PLYMOUTH, MN. - Delve Health Corporation today introduced Study Pal, the industry first cloud application that provides "tip card" information (protocol overview, device/drug and procedure training material, study communications) through a mobile application. Now life science companies can easily provide key trial and product information to investigators and research staff on their smartphone.
Study Pal will help life science companies share trial and product information to investigators and research staff in an accessible format by providing:
Confidentiality – users can login to a website using an authenticated username and password and create their content
Protocol Information – Inclusion/ Exclusion Criteria and key study procedures and data collection requirements
Study Flow – create a flow chart for the study visits
Study Contact – contact study staff in one click to call, text or email directly from the app
Product and Procedure Information – upload your device animation or procedure video directly to Study Pal so investigators can share with referring physicians or patients in real-time.
Visit Schedule – allow research coordinators to create a study visit schedule to automatically calculate follow up windows for all patient visits
Calculations – provide an easy calculation tool for various elements, such as BMI
Training – easy access to all the training material
Compliance – ensure that all parties have the latest protocol revisions
Traceability – track who has logged in, ensure they have received the notifications and comply with protocol guidelines
Cloud Solution – always up to date with the latest features and content
"We were thrilled to release the Study Pal to our clinical sites," said Jennifer Englund, VP of Clinical & Regulatory Affairs at Mardil Medical. "In a time where people always have their phones with them, I am surprised our industry is still printing laminated tip cards to share study information with clinical sites. This tool allows us to share and easily update key study information, and assure there is never confusion associated with version control when protocol and procedures change. As a small company, this tool also gives us a very professional and polished way to communicate with our customers. It is a great resource for our internal team, monitors and physician advisors as well."
"Delve Health is bringing the next generation of study tips and information," said Wessam Sonbol, CEO of Delve Health. "We are fulfilling a significant gap in the industry, by providing a completely configurable mobile app, allowing sponsors and sites to ensure protocol compliance and providing easier access to information. For the first time, Life Science organizations will be able to publish protocol tips, summaries, video, study contact and more simply by the click of a button."
About Delve Health Corporation
Delve Health Corporation is a Minnesota-based technology company, which seeks to provide products through proprietary platform technologies by subscription to users who seek to streamline their research processes by using quality data to conduct faster literature reviews and clinical evaluation reports, pre-qualify sites/investigators for clinical trials or to gain an insight into the life science industry. To learn more about Delve Health, visit www.delvehealth.com or email info@delvehealth.com
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.